Published in Healthcare Mergers, Acquisitions and Ventures Week, April 21st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Sirtex.
Report 1: New data on Sirtex's SIR-Spheres microspheres were presented in a poster session reporting the findings of a new retrospective analysis evaluating liver tolerance to repeated doses of radiation from SIR-Spheres microspheres (90Y-microspheres).
Sirtex's SIR-Spheres microspheres are the only U.S. Food & Drug Administration-approved microsphere therapy for liver tumors that originate in the colon or rectum.
The team analyzed the data...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.